The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer
Status: COMPLETED
Study type: OBSERVATIONAL
Conditions: Breast Neoplasms|Tamoxifen
Interventions: OTHER: Poor Metabolism Status Follow Up Therapy Considerations|OTHER: CYP2D6 Inhibiting Drugs
Sponsor: Medco Health Solutions, Inc.
Collaborators: Laboratory Corporation of America|International Business Machines (IBM)|Indiana University School of Medicine|Mayo Clinic